Current interventional cardiology reports最新文献_第5页

The Efficacy of Directional Atherectomy Prior to Stent Implantation. 定向动脉粥样硬化切除术在支架植入前的疗效。

Current interventional cardiology reports Pub Date : 2000-02-01

Moussa, Moses, Colombo

{"title":"The Efficacy of Directional Atherectomy Prior to Stent Implantation.","authors":"Moussa, Moses, Colombo","doi":"","DOIUrl":"","url":null,"abstract":"Coronary stents have improved the short- and long-term outcomes of patients undergoing catheter-based coronary interventions. However, the use of these devices in complex coronary lesions has also created an incessant form of in-stent restenosis that still defies treatment. Plaque burden has been consistently and reproducibly recognized as an important factor that may incite neointimal proliferation after stent implantation. Prospective nonrandomized experience has shown that plaque removal prior to stent implantation using directional atherectomy is a promising approach to reduce restenosis in selected patients. However, the proof of concept awaits the results of the randomized trials. Ultimately, the clinical use (safety and efficacy) of this approach will depend on 1) further improvements on the current directional atherectomy device to make it user friendly; 2) minimizing the incidence of non-Q-wave myocardial infarction with selective use of IIb-IIIa platelet receptor antagonists or distal protection devices; and 3) targeting patients at high risk for restenosis in whom efficient debulking is feasible. This would include patients who have noncalcified lesions in vessels greater than 2.75 mm but less than 3.5 mm in diameter that require a long stent or multiple stents, aorto-ostial lesions, bifurcational lesions, and chronic total occlusions.","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":"2 1","pages":"20-26"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21920915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low Molecular Weight Heparin and Coronary Intervention. 低分子肝素与冠状动脉介入治疗。

Current interventional cardiology reports Pub Date : 2000-02-01

Garratt

{"title":"Low Molecular Weight Heparin and Coronary Intervention.","authors":"Garratt","doi":"","DOIUrl":"","url":null,"abstract":"For more than 25 years, basic experiments using cell culture and animal experimental techniques have predicted superior thrombin inhibition with use of low molecular weight heparin (LMWH) rather than unfractionated heparin (UFH). This should have application in the cardiac laboratory, where thrombin control is essential to securing a safe and optimal therapeutic angioplasty for patients with atherosclerotic heart disease. Despite much interest, few meaningful clinical studies have been completed and there are limited clinical data to establish the magnitude of benefit actually conferred through use of LMWH rather than UFH among most patients undergoing elective or urgent cardiac catheterization procedures. At this point, the available data suggest minimal clinical advantage is to be gained through the use of LMWH over UFH. Also, obtaining this modest advantage may require an extended period of drug therapy before and after intervention. Any benefit conferred is likely restricted to the period shortly after coronary intervention. On the other hand, available data suggest that serious bleeding should not be problematic despite difficulties measuring that antithrombin effect among patients receiving LMWH, even when it is combined with potent platelet inhibitor therapy. Although cell culture and animal experiments suggest that heparin compounds should be effective in limiting intimal hyperplasia (and therefore clinical restenosis) after angioplasty, randomized clinical trials have failed thus far to show any restenosis benefit for either UFH or LMWH. Ongoing studies will clarify the use of combining LMWH with potent antiplatelet agents as combined medical adjuncts to coronary intervention.","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":"2 1","pages":"49-59"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21920918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fragmin and Other Low Molecular Weight Heparins in Coronary Intervention. Fragmin和其他低分子肝素在冠状动脉介入治疗中的作用。

Current interventional cardiology reports Pub Date : 2000-02-01

Batchelor, Zidar

引用次数: 0

History of the Development of Atrial Septal Occlusion Devices. 房间隔闭塞装置的发展历史。

Current interventional cardiology reports Pub Date : 2000-02-01

Chopra, Rao

引用次数: 0

The Angel Wings Das Devices for Atrial Septal Defect Closure. 天使翼式房间隔缺损闭合装置。

Current interventional cardiology reports Pub Date : 2000-02-01

Das, Harrison, O'Laughlin